People volunteer for Covid-19 surveillance testing using the Quest Diagnostics self administered PCR test on on July 12, 2020 in Livingston, Montana.
William Campbell | Getty Images
Quest Diagnostics reported preliminary second-quarter revenue above analysts’ estimates on Monday, largely on growing demand for its Covid-19 testing services, sending its shares up 2.7% before the bell.
The company said revenue fell 6% to about $1.83 billion, but was still ahead of the average analyst estimate of $1.52 billion, according to Refinitiv I/B/E/S data.
Quest said results also reflected stronger-than-expected recovery in base testing volumes, which have fallen about 34% compared with year-ago period, excluding COVID-19 molecular and antibody testing.
The company had started witnessing a faster-than-expected recovery in its testing volumes in the United States in June, after a more than 40% decline during the last two weeks of March.
Excluding items, the diagnostics company is expecting to earn between $1.39 and $1.42 per share. Analysts are expecting adjusted profit of 12 cents.
Quest is expected to report second-quarter results on July 23.
Get The Best Financial Tips
Straight to your inbox
Subscribe to our mailing list and get interesting stuff and updates to your email inbox.
Thank you for subscribing.